CD36 and metabolic dysfunction-associated steatotic liver disease: Per our knowledge, this novel study looks into fraxin’s efficacy in an “MCD-induced NAFLD mouse model.” Fraxin alleviates NAFLD by regulating “fatty acid translocase/cluster of differentiation 36 (FAT/CD36)” together with gut microbiota.